osimertinib
astrazeneca
['tagrisso']
 only around 40% control recieved tagrisso at cross over because many patients were treated in a 3rd world setting. this trial relies on an inadequately treated control. can t conclude that adjuvant tagresso has os vs salvage.
Radonc